Background: Growth differentiation factor-15 (GDF-15), a stress-responsive transforming growth factor-ß-related cytokine, is elevated and independently related to an adverse prognosis in systolic heart failure.
Introduction
Nearly half of the patients presenting with symptoms and signs of heart failure have a normal ejection fraction (EF) 1, 2 , a condition termed "heart failure with normal ejection fraction (HFnEF)". Recent data suggest that overall mortality due to HFnEF is equivalent to that of systolic heart failure (SHF) 1, 2 . In the general population, asymptomatic left ventricular diastolic dysfunction (LVDD), which is considered as a precursor of HFnEF 3 , is a powerful and independent predictor of death 4 .
Nevertheless, clinical trials in HFnEF have been frequently disappointing, including those with drugs approved for SHF [5] [6] [7] . Notwithstanding the same overall mortality, this is at least in part due to the lower proportion of heart failurerelated death in the overall population of patients with HFnEF 8 . The discrepancies in mortality rates from heart failure-related deaths may be attributed to the considerable heterogeneity among patients with HFnEF, which can be explained by the use of different recruitment criteria 9 or the complexity of echocardiographic diagnosis. Even though a specific guideline has been proposed recently by the American Society of Cardiology 10 , establishing this medical condition is difficult in clinical practice. Echocardiography can be misleading or inconclusive and will not always be sufficient to establish the diagnosis. Better characterization of patients with HFnEF at greatest risk for heart failure-related complications and death could allow more effective use of specific interventions.
Biomarkers reflect distinct disease mechanisms, including neurohumoral activation, inflammation, myocyte injury and extracellular matrix turnover.
Growth differentiation factor 15 (GDF-15) is a member of the transforming growth factor ß (TGF-ß) cytokine super-family and was first cloned as macrophage-inhibitory cytokine-1 11 . Previous studies have shown that patients with SHF have increased circulating levels of GDF-15 12 , and it has been demonstrated that GDF-15 provides prognostic information beyond that established by clinical and biochemical risk factors 13, 14 .
The aim of the present study was to test the diagnostic value of GDF-15 in identifying patients with preclinical, asymptomatic LVDD or HFnEF. Moreover, we analyzed the association of GDF-15 levels to different preload conditions.
Methods
One hundred-nineteen consecutive subjects referred to elective coronary angiography for stable or suspected coronary artery disease (CAD) or diagnostic workup of heart failure were enrolled in the study. Patients that needed coronary revascularization with either angioplasty or coronary bypass surgery were not enrolled in the study. The protocol was approved by the local Ethics Committee, and signed informed consent was obtained from all patients. Exclusion criteria were left ventricular EF < 50%, known CAD with progressive chest pain within the last month, coronary angioplasty or myocardial infarction < 6 weeks, hypertrophic cardiomyopathy, moderate-to-severe valvular heart disease, uncontrolled hypertension, atrial fibrillation or other severe arrhythmias, or serum-creatinine > 2,0 mg/dl. In patients without diabetes, a standardized oral glucose tolerance test (oGTT) was performed (75 g glucose) according to the World Health Organization protocol as previously described 15 . Body mass index (BMI) was calculated as weight (kg)/height (m²).
Echocardiography
Echocardiography was performed using a standard ultrasound system (Vivid 7, General Electric, Milwaukee, Wisconsin). Left ventricular EF was measured based on the modified biplane Simpson's method. The left atrium volume index 16 was calculated using the biplane area-length method 16 . Dimensions were recorded by standard techniques according to current guidelines 17 . Left ventricular mass index (LVMi) was calculated by the Devereux formula indexed to the body surface area 17 . Conventional transmitral flow was measured with pw-Doppler. Early (E), late atrial (A) transmitral peak flow velocities and the ratio (E/A) were measured and three consecutive beats were averaged. Pulsed wave tissue Doppler imaging (TDI) was performed at the junction of the septal and lateral mitral annulus and three consecutive beats were averaged. Early diastolic velocities (E' medial, E' lateral) were recorded; the mean value (E' average) of E' at the medial and lateral mitral annulus was determined. Ratios of E/E' medial, E/E' lateral and average E/E' ratio were calculated. Diastolic dysfunction was classified according to the common consensus study by the American and European Society of Echocardiography (ASE, ESC) 10 .
Inert gas-rebreathing (Innocor™)
A spirometry (Innocor™ device INNO0500) was performed to exclude relevant pulmonary dysfunction. Cardiac output (CO) was measured using an inert gas rebreathing (IGR) device (Innocor™, Innovision A/S, Denmark) in a subgroup with either normal diastolic function or asymptomatic mild LVDD (LVDD grade I, n = 10) and patients with HFnEF (LVDD grade II or III, n = 10). The method has been described in details elsewhere 18 and has been validated in heart failure patients at rest and exertion 19, 20 . For the IGR method, O 2 -enriched test gas with 0.5% N 2 O (blood soluble gas) and 0.1% SF6 (blood insoluble gas) was used. The gas volume was adjusted to meet the physiological demand during rest. Use of SF6 enabled the measurement of the volume of lungs, valve and rebreathing bag. The test gas concentration was decreased during the rebreathing maneuver, with a rate proportional to pulmonary blood flow (PBF). The slope of the N 20 washout kinetics correlates with PBF and CO in the absence of pulmonary shunt.
Prior to the measurements, patients were instructed on the rebreathing technique. The interval for measurements was a minimum of 3 minutes to allow complete inert gas clearance. CO was measured in different body positions as a model of ventricular load change and indexed for body surface area (BSA, COi). After 5 minutes of rest in supine position, CO was measured 3 times, and then body position was changed from supine to upright. After a three-minute period prior to the minimum period necessary to achieve a hemodynamic equilibrium, three consecutive measurements were performed. The measurements were averaged in each position.
Laboratory analysis
Blood samples were drawn at rest for the analysis of routine laboratory parameters and were stored at -80°C for later analysis. After thawing, GDF-15 was measured in plasma with a pre-commercial electrochemiluminescence immunoassay and NT-proBNP with a commercially available electrochemiluminescence immunoassay on an automated Elecsys™ analyzer (all Roche Diagnostics GmbH, Mannheim, Germany) by an investigator blinded to patient characteristics.
Statistical analysis
All analyses were performed using SPSS statistical software (SPSS 17.0, Chicago, IL). The data are presented as medians (interquartile range) for continuous variables or absolute numbers (%) for categorical variables, unless otherwise specified. Log-transformed values were used for analysis as appropriate. A p value < 0.05 was considered statistically significant. Non-parametric tests for group differences between categories were performed. We used the Kruskal-Wallis test to test the equality of medians among more than two distinct groups. The Wilcoxon-Mann-Whitney U-test was used to analyze differences between the medians of two groups and the χ2 test to evaluate differences in proportions in more than 2 sets of categorical variables. Fisher´s Test was used for the comparison of two sets of binary variables.
Growth differentiation factor-15 levels were compared across different grades of LVDD and different categories of the E/e' average ratios and the LAi by the Jonckheere-Terpstra test. We used the Spearman rank correlation to identify variables associated with GDF15. Multivariate analysis of covariance and logistic regression models, including most predictive variable for the dependent variables were built. Multiple linear regression analysis was applied to identify factors that were independently associated with GDF-15 levels.
Results

Patient characteristics
We included 119 patients with normal EF (66 years [59-73]) in the study (45% woman), 63% of whom had CAD without the need for revascularization. Subjects were classified as having either mild LVDD (grade I, n = 61), HFnEF (LVDD grade II or III, n = 38) or normal diastolic function (normal DF, n = 20). Patients with HFnEF were older, had a higher mean NYHA functional class, higher systolic and mean arterial blood pressure values, a lower resting heart rate and were more likely to have diabetes compared to the group with normal DF (all p < 0.005). An oGTT was performed in 80 individuals, of whom 35 (29%) had a normal glucose tolerance (NGT), 31 (26%) had impaired glucose tolerance (IGT) and 24 (20%) had newly detected diabetes. Twenty-nine patients had a history of type 2 diabetes mellitus before inclusion in the study; therefore, 53 (45%) individuals included in the study were identified as having type 2 diabetes mellitus (T2DM).Metabolic syndrome (MetS) was diagnosed in 51% of patients according to the amended National Cholesterol Education Program's Adult Treatment Panel III (ATP-III) 21 . The clinical characteristics in patients classified as to the presence or absence of LVDD or HFnEF are shown in Table 1 , the laboratory data and parameters of cardiac assessment are highlighted in Table 2 .
GDF-15 and diastolic function
In the whole study group, GDF-15 was significantly elevated in HFnEF patients (1.08 [0.88-1.30]) compared to those with normal diastolic function (0.60 [0.50-0.71], p < 0.001) or mild LVDD (0.78 [0.62-1.04], p < 0.001). In addition, GDF-15 plasma levels were higher in subjects with mild LVDD compared to patients with normal diastolic function (p=0.003, Figure 1 ). When excluding subjects with CAD, GDF-15 levels remained significantly associated with the severity of diastolic dysfunction (p < 0.001). The GDF-15 levels were closely related to the New York Heart Association (NYHA) functional class. In a multivariate lineal regression model including variables known to be associated with the presence of LVDD, age (ß = 0.456, p < 0.001) and the presence of mild LVDD or HFnEF (ß = 0.315, p = 0.001) were identified as variables predictive of higher GDF-15 levels. Female gender, the presence or absence of CAD, BMI, a history of T2DM, a previous myocardial infarction, left ventricular muscle mass and hypertension did not add significantly to the model (adjusted r 2 = 0.39, p < 0.001 for overall model).
The relationship between GDF-15 quartiles and clinical echocardiographic characteristics and NT-pro-BNP levels is shown in Table 3 . Increasing quartiles of GDF-15 levels were associated with a higher EF, a higher LAi, a higher E/E' septal and E/E' average ratio and a lower E' septal, lateral and average E' ratio. In addition, GDF-15 quartiles were associated with higher NT-pro-BNP levels. Particularly among the association with echocardiographic parameters of diastolic dysfunction, GDF-15 levels were significantly increased across the LAi and the average E/E' ratio, with both being indicative of elevated left atrial filling pressures (Figure 2a and Figure 2b ). There was a weak linear correlation between the LAi (r = 0.354, p < 0.001) and the average E/E' ratio with GDF-15 levels (r = 0.613, p < 0.001).
In contrast, the global longitudinal strain values, a very sensitive tool to detect subtle systolic dysfunction disregarding a normal EF, were not associated with GDF 15 levels. In addition, parameters of left ventricular geometry (left ventricular mass index, relative wall thickness and left ventricular end diastolic volume index) were not related to GDF-15 concentrations (Table 3 ). 
GDF15 and hemodynamic orthostatic test
Discussion
Growth differentiation factor-15 plasma levels are associated with the diagnosis of HFnEF and LVDD. Furthermore, GDF-15 levels are increased with more severe grades of LVDD and can differentiate subjects with normal DF and asymptomatic LVDD. Growth factor differentiation factor-15 levels correlates with the echocardiographic criteria implemented in the current guidelines for the diagnosis and classification of LVDD. This is the first study to show an association between GDF-15 levels and cardiac output response to different preload conditions serving as a functional parameter of hemodynamic reserve.
Experimental studies have shown that GDF-15 expression significantly increases in the heart after various forms of stress, including pressure overload 22, 23 . Animal studies have shown that GDF-15 promotes protective, antiapoptotic and antihypertrophic effects in the heart 23 . Considering the fact that GDF-15 is produced by several other cell types in addition to cardiomyocytes (endothelial cells, adipocytes, macrophages, vascular smooth muscle cells), it is likely that this biomarker integrates information from different disease pathways, providing a pathophysiological insight in patients with HFnEF.
The human GDF-15 promoter contains two p53 and two Egr1 consensus binding sites 24 . Increased expression of p53 has been detected in the failing human myocardium, and it has been suggested that it plays a role in the transition from cardiac hypertrophy to systolic heart failure 25 . Erg1 is induced in human atherosclerotic plaques 26 and is a mediator of pressure overload hypertrophy in a mice model 27 . Therefore, GDF-15 appears to have cardioprotective functions; those in SHF , GDF-15 might be a future biomarker in patients with HFnEF, probably indicating prognosis.
05). BMI -Body mass index, BP -blood pressure, CAD -Coronary Artery Disease, CABG -coronary bypass graft, DF -diastolic function, HFnEF -heart failure with normal ejection fraction, IGT -impaired glucose tolerance, LVDD -left ventricular diastolic dysfunction, NGT -normal glucose tolerance, HR -heart rate, MAP -mean arterial pressure, OAD -oral anti-diabetic therapy, PTCA -percutaneous coronary angioplasty, T2DM -type 2 diabetes mellitus.
According to the current guidelines, patients can be classified as having HFnEF or LVDD without the need for objective evidence of hemodynamic limitation in exercise tolerance as a result of increasing preload or afterload conditions. Incoherent in the current diagnostic approach is that leading symptoms of patients with HFnEF are related to physical activity 30 , whereas ventricular performance obtained at rest does not accurately reflect exercise tolerance and 
Figure 2b -Growth differentiation factor-15 levels plotted against the E/E´ average ratio. GDF-15 levels are presented as box (25 th percentile, median, 75 th percentile), and whiskers plots and upper outliers are presented as black dots (p < 0.001for trend by Jonckheere-Tepstra). GDF-15 -growth differentiation factor-15.
E/E' average < 8 GDF-15 (ng/ml) E/E' average 9-13 E/E' average > 13 . Consistent with the fact that GDF-15 expression is activated in response to stress 27 , our data showed a significant negative correlation between the magnitude of COi response to the changes in body position from upright to supine, which can be considered a model of preload change. The association of a reduced cardiac output response to preload stress and increased GDF-15 levels confirmed the hypothesis that the adaptive response of GDF-expression is countermanded by the severity of the underlying disease. This is further reinforced particularly by the correlation of GDF-15 and the LAi, a parameter that indicates severe diastolic function abnormalities over a longer period of time. An increased LAi without concomitant mitral valve disease reflects an enduring cumulative effect of different contributors to the development of LVDD and is therefore less vulnerable to intermittent changes in preload (e.g. volume status) or afterload (e.g. blood pressure). Acute changes in these conditions during echocardiographic diagnosis might lead to misclassifications of diastolic function abnormalities.
The finding of an association between GDF-15 and LVDD is in line with a recent study of Stahrenberg et al 32 that assessed the relationship in a community based trial. Nevertheless, there are some concerns about methodological issues that might have influenced the results presented in this interesting study. Most important, there was no general screening for the presence of CAD with either noninvasive stress testing or coronary angiography. Since CAD has been shown to be associated both with elevated GDF-15 levels 28, 33 and LVDD 34 , the lack of information on coronary morphology is a potential source of bias towards increased plasma levels of GDF-15 and toward an increased prevalence and/or severity of LVDD. In accordance with the uncertainties about the presence of CAD, the E/E' ratio was not averaged based on medial and lateral velocities, as recommended by the current guidelines 10 . Because some of the patients likely had regional wall motion abnormalities, tethering effects might have been a possible source of bias. Moreover, patients were not screened with an oral glucose tolerance test for undetected diabetes, which have been associated both with increased GDF-15 levels 35, 36 and the presence and severity of LVDD, especially in subjects with newly detected diabetes on oGTT 37 .
In contrast, the present study followed the current guidelines for the diagnosis of LVDD in subjects well characterized for the degree of abnormality in plasma glucose levels and coronary morphology. Therefore, we were able to reinforce the data of Stahrenberg et al 32 . in a different cohort of patients with known coronary morphology and metabolic status. Furthermore, we extended the findings to a functional hemodynamic parameter, as we were able to demonstrate an association of GDF-15 levels with an impairment of the hemodynamic response to different preload conditions.
Limitations
The number of patients, especially with normal DF in our cohort, was relatively small, resulting in a limited statistical power. Furthermore, the rates of CAD and cardiovascular risk factors were high in this study population. Therefore, the present results may not readily represent the general population. In addition, patients with HFnEF were older than those with normal diastolic function, a potential source of bias towards increased plasma levels of GDF-15. Nevertheless, association between LVDD and GDF-15 remains significant after adjustment for CAD, age, glucose metabolism and hypertension as covariates into multivariate regression models. Although we based the diagnosis of LVDD on current guidelines which have recently been published, their clinical value has yet to be prospectively validated. Furthermore, the rate of patients on antihypertensive treatment was higher in the HFnEF group. Nevertheless, a significant relation of any of these drugs to the increased GDF-15 plasma levels has never been identified. Lastly, our cross sectional study design does not permit any conclusions on causality.
Conclusion
GDF-15 is a novel promising biomarker in HFnEF that is elevated in subjects with either mild or moderate to severe LVDD regardless of the presence of CAD or other established risk factors frequently associated with HFnNF. Considering the fact that GDF-15 appears to have cardioprotective functions, we hypothesize that higher levels of GDF-15 may reflect an adaptive response that is outweighed by the severity of the underlying disease. Incorporating a biomarker to aid in diagnosis, and risk prediction in HFnEF may enhance the ability to accurately and early identify patients at greatest risk for heart failure-related complications. Better characterization of patients with HFnEF could allow a more effective use of specific therapeutic and prevention strategies. Further studies are needed to determine the value of GDF-15 for diagnosis and therapy monitoring in diastolic heart failure.
